Philip Komarnitsky
Chief Medical Officer Nested Therapeutics
Seminars
Wednesday 17th September 2025
Pan-Raf-MEK Non-Degrading Molecular Glue NST-628: Pre-Clinical Modelling & Incorporation of PD, ctDNA & Circulating Tumor Markers in Guiding Dose Escalation & Patient Selection in the FIH Clinical Study
4:00 pm
- Design of Phase 1 NST-628 first-in-human clinical study
- Approach to modelling of target NST-628 exposures based on tumor growth inhibition and surrogate PD markers in xenografts
- Dose dependence of NST-628 effect on ctDNA, PD and circulating tumor markers and application for patient selection
